Follicle Stimulating Hormone Market Report 2025

The follicle stimulating hormone market size has grown strongly in recent years. It will grow from $2.03 billion in 2024 to $2.14 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to increased prevalence of hormonal disorders, growing demand for fertility treatment, expansion of FSH indications, market entry of new FSH products, growing demand for safe and effective contraceptive options.

The follicle stimulating hormone market size is expected to see strong growth in the next few years. It will grow to $2.64 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to widening therapeutic applications, rising demand for combination therapy, growing need for effective contraceptive options, aging population and related healthcare needs, market expansion in key regions. Major trends in the forecast period include advanced biosimilar FSH products, regulatory approvals and market access, technological advancements in FSH production and delivery, growing need for effective contraceptive options.

The anticipated growth in the follicle-stimulating hormone market is expected to be propelled by the increasing prevalence of infertility. Infertility, a condition impacting the male or female reproductive system, is characterized by the inability to conceive after 12 months or more of frequent, unprotected sexual contact. Follicle-stimulating hormone plays a crucial role in encouraging egg development in the ovaries and regulating the menstrual cycle in females. In men, it promotes testicular growth and assists in the production of a protein essential for male fertility by supporting the development of healthy sperm cells. Notably, as of April 2023, the World Health Organization reported that infertility affected approximately 1 in 6 adults globally, accounting for around 17.5% of the adult population. Moreover, data from the Australian Bureau of Statistics in October 2023 indicated a 3% decrease in recorded births in 2022, with an overall fertility rate of 1.63 births per woman. Consequently, the increasing prevalence of infertility is a driving force behind the growth of the follicle-stimulating hormone market.

The growing adoption of assisted reproductive technology (ART) is anticipated to drive the expansion of the follicle-stimulating hormone market in the coming years. ART refers to medical procedures or practices that assist individuals or couples in conceiving when traditional methods have not been successful. The use of follicle-stimulating hormone in ART is a well-established therapy aimed at improving the chances of successful pregnancies for those facing reproductive challenges. For example, in March 2024, the U.S. Department of Health and Human Services reported that the use of ART increases with maternal age. In 2023, 9% of live births among women aged 40-45 were achieved through ART, with that number rising to nearly one-third for women aged 45 and older. Additionally, ART usage varies by region across the U.S. As a result, the increasing adoption of assisted reproductive technology is significantly impacting the follicle-stimulating hormone market.

Product innovations are a significant trend gaining traction in the follicle-stimulating hormone market. Leading companies in this sector are concentrating on developing innovative products to enhance their market position. For instance, in July 2024, Proov, a U.S.-based women's health company, introduced the Proov Empower Perimenopause Testing System. Proov Empower provides comprehensive and personalized insights into how a woman's changing hormones impact her overall health and wellness. This non-invasive, multi-time point urine test measures four key hormones - FSH, estrogen marker E1G, progesterone marker PdG, and LH - that affect symptoms and the perimenopause experience. By facilitating periodic retesting, Proov Empower enables women to monitor hormone fluctuations and symptoms, acting as a valuable resource during the transition to menopause.

Major companies in the follicle-stimulating hormone market are also investing in the development of groundbreaking products such as estrogen-based pills to augment their product offerings and gain a competitive edge. Estrogen-based pills, containing the essential hormone for the growth and management of the female reproductive system, represent a notable innovation. In August 2022, Myovant Sciences Ltd., a UK-based biopharmaceutical company, and Pfizer Inc., a US-based pharmaceutical and biotechnology firm, announced the US Food and Drug Administration (FDA) authorization for MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a one-pill treatment. MYFEMBREE serves as a once-daily medication for the treatment of moderate to severe pain caused by endometriosis in premenopausal women for up to 24 months. Additionally, it is authorized for premenopausal women experiencing excessive menstrual bleeding due to uterine fibroids. Myovant and Pfizer intend to jointly market MYFEMBREE in the United States.

In September 2024, Organon China, a healthcare company based in China, partnered with Shanghai Bao Pharmaceutical to develop SJ02, a Long-Acting FSH currently in the BLA process. This innovative investigational asset targets the assisted reproductive technology (ART) market in mainland China. Through this partnership, Organon is advancing its "In China, for China" strategy while expanding its fertility portfolio. By collaborating with leading innovators in China, Organon aims to accelerate advancements in ART and offer additional fertility options to millions of Chinese families. Shanghai Bao Pharmaceutical is a provider of follicle-stimulating hormone (FSH) based in China.

Major companies operating in the follicle stimulating hormone market include Pfizer Inc., Novartis AG, Abbott Laboratories, Sanofi S.A., Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Cipla Ltd., Ferring Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Livzon Pharmaceutical Group Inc., Emcure Pharmaceuticals Ltd., LG Chem's life sciences, IBSA Group, Bharat Serums and Vaccines Limited, Anhui Anke Biotechnology Group Co. Ltd., Taj Pharmaceuticals Ltd., Genpharm Inc., Cadwell Laboratories Inc., Creative BioMart, Lee Biosolutions Inc., Trumac Healthcare, Midas Pharma GmbH, Biogenix Inc. Pvt. Ltd., Shanghai Techwell Biopharmaceutical Co. Ltd.

North America was the largest region in the follicle stimulating hormone market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the follicle stimulating hormone market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the follicle stimulating hormone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Follicle-stimulating hormone (FSH) is a hormone secreted by the pituitary gland, playing a crucial role in sexual maturation and reproduction. It influences the functioning of the testicles and ovaries, particularly in regulating egg production in the ovaries and the menstrual cycle.

The primary types of follicle-stimulating hormones include recombinant FSH and urinary FSH. Recombinant FSH is a form of FSH produced using recombinant DNA technology, as opposed to being derived from natural sources such as urine. These hormones find application in various areas, including infertility treatment, assisted reproductive technology (ART), and other medical contexts. They are utilized by diverse end-users, including infertility centers, hospitals, and similar institutions.

The follicle stimulating hormone market research report is one of a series of new reports that provides follicle stimulating hormone market statistics, including follicle stimulating hormone industry global market size, regional shares, competitors with a follicle stimulating hormone market share, detailed follicle stimulating hormone market segments, market trends and opportunities, and any further data you may need to thrive in the follicle stimulating hormone industry. This follicle stimulating hormone market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The follicle-stimulating hormone market consists of sales of luteinizing hormone (LH), chorionic gonadotropin (CG), and thyroid-stimulating hormone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.